News | December 15, 2022
China aims to lead next bio revolution in advanced biologics, says GlobalData
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
One in two women with advanced ovarian cancer has an HRD-positive tumor
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The company was directed to submit a plan of compliance by July 15, 2022
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Tislelizumab is now approved in nine indications in China
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Subscribe To Our Newsletter & Stay Updated
